We are pleased to announce the recent publication by Dr. med. Guido Freckmann from Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH at the University in Ulm of the performance of our device which was presented at ADA 9th Scientific Sessions in San Francisco in June 2019.
The aim of the study was to assess the measurement accuracy of our NIGM prototype system in a mixed in clinic/outpatient setup, where the data from the last in clinic visit was blinded prospective independent validation.
Comparable Results to Contemporary CGM
Outpatient mean ARD ranged from 8.0% to 26.2% for Freestyle Libre (FL) (mean: 16.1%) and from 9.1% to 26.9% for RSP prototype (mean:20.2%). In-clinic MARD ranged from 13.7% to 45.3% for FL (mean 23.3%) and from 19.8% to 36.0% for our prototype device (mean: 25.5%).
"This is an important step further, to realise our goal to provide an innovative non-invasive glucose monitor", said Stefan Ovesen Banke, CFO of RSP Systems.